More Effective
Better safety
Less expensive
Dr. Mewa Singh
CEO
www.nanomeda.com
Improving companion animal
treatment and fulfilling the
Veterinarian’s need to treat
cancer in pets
The problem:
a proven effective human therapy is unavailable to canine
patients
Paclitaxel (Taxol) was administered to 25 dogs with histologically confirmed
malignant tumors at a dosage of 165 mg/m2 i.v. over 3-6 hours every 3 weeks. Dogs
received premedication with antihistamines and corticosteroids to reduce
hypersensitivity reactions. However, 64% of the dogs still experienced allergic
reactions. Six dogs (24%) had grade 3 or 4 neutropenia, 6 dogs (24%) required
hospitalization and 3 dogs (12%) died of sepsis. Five dogs (20%) had a partial
response (osteosarcoma [2 dogs] mammary carcinoma [2 dogs] and malignant
histiocytosis [1 dog] for a median duration of 53 days. The overall toxicity was
unacceptable at the 165 mg/m2 dose. Therefore, subsequent evaluations of
paclitaxel in tumor-bearing dogs should a starting dose of 132 mg/m2 i.v. every 3
weeks.
J Vet Intern Med. 2004 Mar-Apr;18(2):219-22.
Efficacy and toxicity of paclitaxel (Taxol) for the treatment of canine malignant tumors.
Poirier VJ1, Hershey AE, Burgess KE, Phillips B, Turek MM, Forrest LJ, Beaver L, Vail DM.
1
Department of Medical Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, 2015 Linden Drive,
Madison, WI 53706, USA.
A Solution
TaxolCurTM formulation is
soluble in water without
a toxic carrier
Opportunity
What animal drugs are eligible for conditional approval?
Only drugs for minor species or minor uses in a major species are
eligible for conditional approval.
Minor species are all animals that are not one of the seven major
species: horses, dogs, cats, cattle, pigs, turkeys, and chickens.
A minor use in a major species is the use of a drug in a major
species for a condition that occurs: Infrequently and in only a
small number of animals each year; or in a limited geographic
area and in only a small number of animals each year.
A drug to control pain in dogs with bone cancer is eligible for
conditional approval because fewer than 70,000 dogs typically
get bone cancer each year.
Accomplished (October 2019)
1. R&D
2. Manufacturing
3. Pre-clinical
TaxolCurTM is available as a stabilized lyophilized product with an
extended safe shelf life and is reconstituted before use with sterile water
Lyophilized crystals (freeze-dried)
Low cost manufacturing for affordability to masses
Quality Analysis
Zeta Potential
HPLC TaxolCur
Time
5 minutes
Dissolution
Dramatic efficacy with TaxolCurTM
Pancreatic Cancer
L3.6pl
TaxolCurTM
Initial dose of 10 mg/kg q4d was
increased to 20 mg/kg, day 18
CurNanoTM
maintenance therapy
DOT
TaxolCur
TM
Active drug dosing (paclitaxel) was
stopped and only curcumin was dosed
through end of study – no recurrence
Pancreatic cancer – orthotopic model with a highly aggressive human
CDX L3.6pl
Improved formulation with greater efficacy and reduced side effects
October 2019 NanoMeda Inc.
TaxolCurTM is efficacious in preventing tumor growth
Treated
Normal pancreas remained
Untreated
Day 16*
No normal pancreas left
Note that the spleen is clearly visible and normal with little tumor evident in the
treated animals (green circles), whereas it is subsumed by the tumor growth in the
placebo / control animals.
* 15/20 treated animals were still alive at Day 42 while 17/20 of the control animals were dead
TaxolCurTM is safe, animals were healthy and
maintained weight
Both groups above were treated for 45 days with TaxolCur and then
had no treatment or were placed on curcumin maintenance therapy.
L3.6PL Orthotopiic Pancreatic Cancer Survival Graph
with TaxolCur™ treatment (IP, q4d)
No survival benefit at 10 mg/kg dose
Percent survival
100
Survival benefit at 20 mg/kg dose
80
60
40
20
0
0
5
10
15
20
25
30
35
40
DOT
Dose increased from 10 mg/kg to 20 mg/kg
Group 1 - Vehicle
Group 2 - Nano
Paclitaxol @ 10 to 20mg/kg
TaxolCur™
TM
TaxolCur
is more effective than Abraxane®
Mew-Paxel is TaxolCurTM
At half the Abraxane dose, Panc-1 pancreatic cancer flank xenograft was effectively t
Previous study conducted at Northwestern University Discovery Technology Center
Possible to track drug in system
I would remove this slide from the presentation until and unless we can get much better
images (and it would require purchase of filters for Woodland)
Hybrid-NanoEngineering™
Combination therapies are fast becoming the cornerstone of a next wave cancer treatments, but why
are they so important?
We know that precisely targeting drivers of cancer can improve patient responses – a good example is
the use of EGFR inhibitors in EGFR mutated tumors – however, cancer is a complex and evolving
disease which can limit the effectiveness of monotherapy which usually fail after some time.
Using combinations of drugs to inhibit different cancer mechanisms has the potential to target distinct
tumor cell populations and shut down bypass mechanisms that enable cancer cells to escape death.
TM
TM
TaxolCur is a drug designed to have two active agents for treating cancer. TaxolCur is a
combination of a well-studied and effective chemotherapy with a natural product that has shown
promise in treating some types of cancer and providing benefits to support chemotherapy.
From The Mayo Clinic
Can curcumin slow cancer growth?
Answer From Timothy J. Moynihan, M.D.
At this time, there isn't enough evidence to recommend curcumin for preventing or treating cancer, but research is
ongoing.
Curcumin, a substance found in the spice turmeric, has long been used in Asian medicine to treat a variety of maladies.
Now some research suggests that curcumin may help prevent or treat cancer.
Curcumin is thought to have antioxidant properties, which means it may decrease swelling and inflammation. It's being
explored as a cancer treatment in part because inflammation appears to play a role in cancer.
Laboratory and animal research suggests that curcumin may prevent cancer, slow the spread of cancer, make
chemotherapy more effective and protect healthy cells from damage by radiation therapy. Curcumin is being studied
for use in many types of cancer.
Studies of curcumin in people are still in the early stages. Clinical trials are underway to investigate curcumin as a way to
prevent cancer in people with precancerous conditions, as a cancer treatment, and as a remedy for signs and symptoms
caused by cancer treatments.
https://www.mayoclinic.org/diseases-conditions/cancer/expert-answers/curcumin/faq-20057858
MEDA BIOTECH INC. CONTACT:
DR. MEWA SINGH
609-902-7128
MYNANOVIEW@GMAIL.COM
Data presented herein have been reviewed and approved by:
Dr. Michael R. Briggs, President & CSO , Woodland
Biosciences